Baxter International has completed the spin-off of its kidney care division as Vantive, a standalone company listed on Nasdaq, allowing Baxter to focus on its acute care, medication delivery and surgical products businesses.
Baxter International has completed the separation of its global kidney care division as Vantive, a newly independent publicly traded company that began trading on Nasdaq under the ticker VNTV.
Vantive becomes one of the largest dedicated kidney care companies globally, with $4.9 billion in annual revenue across peritoneal dialysis (PD), haemodialysis (HD), continuous renal replacement therapy (CRRT) and acute kidney injury treatments.
Vantive at a Glance
- Annual revenue: $4.9 billion
- Patients served: 4.8 million in 120 countries
- Products: AMIA PD system, HomeChoice CLARIA, SHARESOURCE remote monitoring
- Employees: 36,000
- Manufacturing: 12 plants across US, Germany, China, India
Baxter, post-separation, will retain its hospital products, medication delivery, infusion systems and surgical solutions businesses, with approximately $8.8 billion in revenue and a sharpened strategic focus on critical care settings.
Baxter CEO José Almeida stated the separation unlocks significant value for both companies by enabling each to pursue tailored capital allocation strategies aligned to their distinct growth profiles.